Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.
$SGMO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $7.00 | Hold → Buy | Truist |
| 12/10/2024 | $10.00 | Buy | H.C. Wainwright |
| 11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
| 2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
| 1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
| 6/13/2022 | $5.00 | Neutral | Wedbush |
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales. Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Con
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web
424B5 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
SCHEDULE 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00
H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00
RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe
Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets. Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing. Investigational new drug (IND) application cleared by U.S. Food and Drug Administrati
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)